BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Frazier Life Sciences Commits $1B to Nurturing New Biotech Companies

  In total, FSI XI has netted over $987 million in commitments to drive the success of Frazier’s ongoing investment strategy.

  March 16, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano
• 

  Policy

  Novartis, Lilly, Merck and More Halt Business Operations in Russia

  More pharmaceutical companies are joining to put economic pressure on Russia by suspending some or all operations within that country following the invasion of Ukraine.

  March 16, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  COVID-19 Isn’t Done with Us Yet, Vaccine Patents and a 4th Booster

  Now that Omicron is becoming less common, its sister variant, BA.2, seems to be surging worldwide and in the U.S. For that and more, continue reading.

  March 16, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Four Cancer Clinical Trials Advance with Blessing of FDA

  Several biopharma companies celebrate the U.S. Food and Drug Administration’s approval for clinical trials involving therapeutics for cancer treatment.

  March 16, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Business

  Global Roundup: Oxford Hub Expanding into “Ideal Environment” for Life Sciences Companies

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  March 16, 2022

   · 

  6 min read

   · 

  Alex Keown
• 

  Drug Development

  Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results

  After reviewing the trial’s Independent Data Monitoring Committee, the EMPA-KIDNEY trial announced it would stop early as it met prespecified criteria for positive efficacy.

  March 16, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  New NurOwn Data Backs Up Importance of UNC13A in ALS

  BrainStorm Cell Therapeutics’ NurOwn has taken the amyotrophic lateral sclerosis (ALS) community by storm with new genetic data from its Phase III trial.

  March 16, 2022

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Business

  Book Review: Warp Speed – One of the Most Successful Private-Public Partnerships

  In his new book, Warp Speed, Paul Mango said the realization that many healthcare workers didn’t want the vaccine, for instance, was shocking.

  March 16, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Business

  Shoreline Poaches Pfizer Cancer Vaccine Head, Robert Hollingsworth

  Robert Hollingsworth, PhD, a former Pfizer executive who oversaw the development of cancer vaccines and immunotherapeutics, has taken on the role of the CSO at Shoreline Biosciences.

  March 16, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  New Data from Biogen Supports Aduhelm’s Clinical Effectiveness

  Biogen reported new data from a long-term extension phase of the Phase III clinical studies of Aduhelm (aducanumab) for Alzheimer’s disease.

  March 16, 2022

   · 

  3 min read

   · 

  Mark Terry